Pathogenesis and treatment of systemic sclerosis;Patogeneza I leczenie twardziny układowej

Reumatologia

Volumn 41, Issue 2, 2003, Pages 160-176

  Wisłowska, Małgorzata ^a  

^a CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

Author keywords

Interstitials lung disease; Pulmonary hypertension; Renal crisis; Sclerodermia

Indexed keywords

COLCHICUM EXTRACT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; INTERFERON; PENICILLAMINE; PROSTACYCLIN;

DIALYSIS; DRUG EFFICACY; GENETIC PREDISPOSITION; HUMAN; IMMUNOPATHOLOGY; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PATHOGENESIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SURVIVAL; SYSTEMIC SCLEROSIS;

EID: 0038374445     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Akesson A., Wollheim FA., Thysell H.: Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis. Scand. J. Rheumatol., 1988, 17, 313.
2. Akesson A., Scheja A., Lundin A. et al.: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum., 1994, 37 729.
3. Altmann R.D., Medssger T.A. Jr, Bloch D.A. et al.: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum., 1996, 39, 1151.
4. Badesch D.B., Victor F.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum od disease. Ann. Intern. Med., 2000, 132, 425.
5. Basoti G. et al.: Esophageal dysfunction in scleroderma: relationship with disease subset. Arthritis Rheum., 1997, 40, 2252.
6. Black C.M., Silman A.J., Herrick A.I. et al.: Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 1999, 42, 299.
7. Blocka K.L.N., Bassett L.W., Furst D.E.: The arthropathy of advanced progressive systemic sclerosis: A radiographic survey. Arthritis Rheum., 1981, 24, 874.
8. Bruckdorfer K.R., Hillary J.B., Bunce T. et al.: Increased susceptibility to oxidation of low - density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum., 1995, 38, 1060.
9. Bunn C.C., Black C.M.: Systemic sclerosis an autoantibody mosaic. Clin. Exp. Immunol., 1999, 117, 207.
10. Channick R.N., Simonneau G., Sitbon O.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 2001, 358, 1119.
11. Clements P.J., Furst D.E., Wong W.K. et al.: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum., 1999, 42, 1194.
12. Clements PJ. et al.: Skin thickness as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum., 2000, 43, 2245.
13. Cooper G.S., Germolec D., Heindel J. et al.: Linking environment agents and autoimmune diseases. Environ. Health Perspect., 1999, 107, 659.
14. Denton C.P., Black C.M.: Systemic sclerosis: recent clinical and scientic advances. In: Rheumatology Highlights 1999-2000, ed. Emery P. Health Press, Oxford 2000, 51-60.
15. Distler O., Scheid A., Del Rosso A. et al.: HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc. Arthritis Res., 2002, Suppl. 1, A1, 4.
16. Fleischmajer R., Perlish J.S.: Capillary alterations in scleroderma. J. Am. Acad. Dermatol., 1980, 2, 161.
17. Follansbee W.P., Miller T.R., Curtiss E.I. et al.: A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma) J. Rheumatol., 1990, 17, 656.
18. Gabrielli A., Svegliati S., Cancello R. et al.: The Ras oncogene network, reactive oxygen species and the fibrotic stage of scleroderma. Ann. Rheum. Dis., 2002, 61, suppl. 1, 10.
19. Galie N., Humbert M., Vechiery J.L.: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol., 2002, 39, 1496.
20. Gerber I., Gratwohl A., Tyndall A. et al.: Hematopoietic stem cell transplantation in systemic sclerosis (SSc) - an international prospective randomized controlled multicenter study - the ASTIS trial. Ann. Rheum. Dis., 2002, 61, suppl. 1, 5.
21. Giacomelli R., Valentini G., Salsano F. et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J. Rheumatol., 2002, 29, 731.
22. Harrison N.K., Glanville A.R., Strickland B. et al.: Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir. Med., 1989, 83, 403.
23. Harrison N.K., Laurent G.J., Evans T. W.: Transpulmonary gradient of type III procolagen peptides: acute effects of cardiopulmonary bypass. Intensive Care Med., 1992, 18, 290.
24. Herrick A.L.: Vascular function in systemic sclerosis. Curr. Opin. Rheumatol., 2000, 12, 527.
25. Hochberg M.C., Perlmutter D.L.: The association of augmentation mammoplasty with connective tissue disease, including systematic sclerosis (scleroderma); a meta-analysis. Curr. Top. Microbiol. Immunol., 1996, 210, 411.
26. Kahaleh M.B., Fan PS.: Mechanism of serum-mediated endothelial injury in scleroderma: identyfication of a granular enzyme in scleroderma skin and sera. Clin. Immunol. Immunopathol., 1997, 83, 32.
27. Kallenberg C.G.M., Wonda A.A., Hoer M.H. et al.: Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six-year follow-up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann. Rheum. Dis., 1988, 47, 634.
28. Kawaguchi Y., Suzuki K., Hara M. et al.: Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann. Rheum. Dis., 1994, 53, 506.
29. Kleinn H.A. et al.: Comparative studies of esophageal function in systemic sclerosis. Gastroenterology, 1992, 102, 1551.
30. Marie I., Levesque H., Ducrotte P. et al.: Gastric involvement in systemic sclerosis: a prospective study. Am. Gastro., 2001, 96, 77.
31. Mitchell H., Bolster M.B., LeRoy E.C.: Scleroderma and related conditions. Med. Clin. N. Am., 1997, 81, 129.
32. Morrow J., Nelson J.L., Watts R. et al.: Scleroderma in Autoimmune Rheumatic Disease. Oxford University Press, Oxford 1999, 194-215.
33. Murrell D.F.: A radical proposal for the pathogenesis of scleroderma. J. Am. Acad. Dermatol., 1993, 28, 78.
34. Nieterl P.J., Richard M., Silver M.: Twardzina układowa - środowiskowe i zawodowe czynniki ryzyka. Curr. Opin. Rheumatol. (wydanie polskie), 2001, 1, 5.
35. Olschewski H., Walmrath D., Schermuly R. et al.: Aerosolized prostacyclin and iloprost in severe pulmonary hypertention. Ann. Intern. Med., 1996, 124, 820.
36. Rich S., Kaufmann E., Levy P.S.: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med., 1992, 327, 76.
37. Rubin L.J., Mendoza J., Hood M.: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med., 1990, 112, 485.
38. Rubin L.J., Badesch D.B., Barst R.J. et al.: Bosentan therapy for pulmonary arterial hypertention. N. Engl. J. Med., 2002, 346, 896.
39. Sambo P., Jannino L., Candela M. et al.: Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J. Invest. Dermatol., 1999, 112, 78.
40. Sambo P., Baroni S.S., Luchetti M. et al.: Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum., 2001, 44, 2653.
41. Seibold J.R., Clements PJ., Furst D.E. et al.: Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J. Rheumatol., 1998, 25, 302.
42. Silver R.M.: Clinical problems. The lungs. Rheum. Dis. Clin. North Am., 1996, 22, 825.
43. Silver R.M., Warrick J.H., Kinsella M.B. et al.: Cyclophosphamide and low dose prednisone therapy in systemic sclerosis (scleroderma) patients with interstitial lung disease. J. Rheumatol., 1993, 20, 838.
44. Simon J., Gibbs R.: Recomendation on the management of pulmonary hypertention in clinical practice. Heart, 2001, 86, suppl. 1, 11.
45. Simonneau G., Barst R.J., Galie N.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controllled trial. Am. J. Respir. Crit. Care Med., 2002, 165, 800.
46. Steen V.D. et al.: Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann. Intern. Med., 1990, 113, 352.
47. Steen V.D., Conte C., Owens G.R. et al.: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum., 1994, 37, 1283.
48. Steen V.D., Lanz J.K. Jr, Conte C. et al.: Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum., 1994, 37, 1290.
49. Steen V.D.: Renal involvement in systemic sclerosis. Clin. Dermatol., 1994, 12, 253.
50. Stein C.M., Tanner S.B., Awad J.A. et al.: Evidence of free radical - mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum., 1996, 39, 1146.
51. Varai G., Earle L., Jimenez S.A. et al.: A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J. Rheumatol., 1998, 25, 1325.
52. Weston S. et al.: Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am. J. Gastroenterol., 1998, 93, 1085.
53. White B., Moore W.C., Wigley F.M. et al.: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med., 2000, 132, 947.
54. Wigley F.M., Seibold J.R., Wise R.A. et al.: Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J. Rheumatol., 1992, 19, 1407.